Posted by Michael Wonder on 09 Mar 2025
Novo Nordisk to sell obesity drug Wegovy direct to patients at lower price
5 March 2025 - Move follows similar announcement by Eli Lilly, though Novo’s is broader.
Novo Nordisk will start selling its obesity drug Wegovy directly to patients at a reduced price, following a similar move from Eli Lilly as the two drug makers compete for market share and try to draw patients away from compounding pharmacies that have been making cheaper copies of weight loss drugs.
Wegovy normally carries a list price of about $1,350/month, but Novo will sell the treatment through its new direct to consumer offering called NovoCare Pharmacy at $499/month for all doses to cash-paying patients, meaning patients who are paying on their own without insurance.
